Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Condor Announces Kumli Field Extension With Successful K-42 Pilot Well

June 15, 2026

Game Starts! 2026 World Cup Frenzy: ALL IN THE GLORY

June 15, 2026

Multiple people injured at water park in Cultus Lake, RCMP say

June 15, 2026

Big Tech’s desperate last push at AI regulation

June 15, 2026

ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea 

June 15, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Europe Next Generation Sequencing Market Forecasts Report 2024-2032, Substantial Growth Projected with Advancements in Genomic Research and Personalized Medicine
Press Release

Europe Next Generation Sequencing Market Forecasts Report 2024-2032, Substantial Growth Projected with Advancements in Genomic Research and Personalized Medicine

By News RoomDecember 4, 20243 Mins Read
Europe Next Generation Sequencing Market Forecasts Report 2024-2032, Substantial Growth Projected with Advancements in Genomic Research and Personalized Medicine
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) — The “Europe Next Generation Sequencing Market Report by Products, Application, Technology, End-users, Country and Company Analysis 2024-2032” report has been added to ResearchAndMarkets.com’s offering.

The European Next Generation Sequencing (NGS) market is experiencing significant growth due to technological advancements in genomic research. The enhanced capabilities of sequencing technology have enabled faster, more accurate, and cost-effective analysis. These strides have led to accelerated discoveries in personalized medicine, cancer research, and the investigation of rare genetic disorders. As European research institutions and biotechnology firms continually leverage these cutting-edge technologies, the demand for NGS products and services is expected to rise and contribute to the overall market growth.

Growing Prevalence of Genetic Disorders Increases NGS Demand

With the rise in the incidence of various genetic disorders, the demand for Next Generation Sequencing is intensifying within Europe. NGS provides comprehensive and precise genetic data essential for the diagnosis and treatment of inherited cancers, rare diseases, and congenital conditions. The increasing demand for genetic testing and the shift towards personalized medicine are catalyzing the NGS market, as healthcare providers seek improved diagnostic tools to refine patient care.

NGS Advances Personalized Medicine in Europe

Personalized medicine, informed by a patient’s genetic make-up, continues to be a significant growth driver for the European NGS market. Next-Generation Sequencing technologies offer essential genetic insights, facilitating the development of personalized medicine strategies and targeted therapies. These innovations are propelling healthcare facilities to invest in NGS solutions, thereby fueling the market’s growth. This is evidenced by greater precision in diagnosis and treatment, which benefits both patients and healthcare providers alike.

Germany Dominates European NGS Market

Germany is poised to be a leader in the NGS market, as both public and private sector entities widely adopt genomics. The high-throughput capabilities of NGS technologies are highly advantageous for cancer research, genetic disease studies, and personalized medicine. This adoption is further supported by government grants and subsidies for genomic research. The German market’s robust growth is anticipated to continue, with the country playing a pivotal role in innovating healthcare services and advancing personalized treatments.

Top Companies Strengthen European NGS Sector

Prominent industry players, including Illumina, Thermo Fisher Scientific, Pacific Biosciences of California, QIAGEN N.V, Roche, and others, are making strides in the NGS space. Recent developments in the sector include the launch of permanent reimbursement for NGS in oncology in Belgium and significant investments by Almac Diagnostic Services to expand NGS capabilities. Innovations such as the integration of the latest sequencing chemistry further demonstrate these companies’ dedication to advancing the NGS market in Europe.

The Next Generation Sequencing market is a testament to the robust and collaborative efforts between genomic research, technological advancements, and healthcare applications. The symbiotic relationship between these domains is shaping a promising future for NGS in Europe and globally.

Key Attributes:

Report Attribute Details
No. of Pages 200
Forecast Period 2023 – 2032
Estimated Market Value (USD) in 2023 $4.58 Billion
Forecasted Market Value (USD) by 2032 $12.95 Billion
Compound Annual Growth Rate 12.2%
Regions Covered Europe

Companies Featured

  • Illumina
  • Thermo Fisher Scientific
  • Pacific Biosciences of California
  • QIAGEN N.V
  • Roche
  • Bio-Rad Laboratories, Inc.
  • Takara Bio Inc.
  • Hamilton Company
  • Geneious,
  • BioMérieux SA.

For more information about this report visit https://www.researchandmarkets.com/r/masdp5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • European Next Generation Sequencing Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Condor Announces Kumli Field Extension With Successful K-42 Pilot Well

Game Starts! 2026 World Cup Frenzy: ALL IN THE GLORY

ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea 

Wix Partners with Microsoft 365 Copilot to Bring Website Creation into the Flow of Work

biBerk Business Insurance Offers Key Insights on Business Interruption Insurance, Why it’s Essential, Coverage Costs, and the Claims Process

Fast Hippo Media Acquires Plano Website Design, Expanding Its DFW Footprint and AI Search Leadership

Carl Moon Announces First Ferrari Challenge Podium Finish Achieved During Le Mans Race Week

Martensen IP Offers Strategic Insights on Defining the Nature of Teaming Agreements, Critical Intellectual Property Issues, and the Risks of Strategic Alliances in Government Contracts

Slate360 Provides Insights on How To Make a Memorable First Impression With Tradeshow Attendees, Navigating Difficult Conversations, and the Importance of the Post-Show Debrief

Editors Picks

Game Starts! 2026 World Cup Frenzy: ALL IN THE GLORY

June 15, 2026

Multiple people injured at water park in Cultus Lake, RCMP say

June 15, 2026

Big Tech’s desperate last push at AI regulation

June 15, 2026

ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea 

June 15, 2026

Latest News

Wix Partners with Microsoft 365 Copilot to Bring Website Creation into the Flow of Work

June 15, 2026

biBerk Business Insurance Offers Key Insights on Business Interruption Insurance, Why it’s Essential, Coverage Costs, and the Claims Process

June 15, 2026

Fast Hippo Media Acquires Plano Website Design, Expanding Its DFW Footprint and AI Search Leadership

June 15, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version